Scienture Holdings, Inc. (SCNX)
NASDAQ: SCNX · Real-Time Price · USD
3.170
+0.045 (1.44%)
Nov 9, 2026, 2:53 PM EST - Market open
Scienture Holdings Revenue
Scienture Holdings had revenue of $343.64K in the quarter ending June 30, 2026. In the year 2025, Scienture Holdings had annual revenue of $431.61K with 215.87% growth. That makes Scienture Holdings the 43,936th largest company in the world by revenue and 6,175th in the United States.
Revenue (ttm)
$431.61K
Revenue Growth
+215.87%
P/S Ratio
6.25
Revenue / Employee
$91,257
Employees
9
Market Cap
5.21M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 431.61K | 294.97K | 215.87% |
| Dec 31, 2024 | 136.64K | -1.23M | -89.98% |
| Dec 31, 2023 | 1.36M | -8.89M | -86.69% |
| Dec 31, 2022 | 10.25M | 360.74K | 3.65% |
| Dec 31, 2021 | 9.89M | -7.23M | -42.24% |
| Dec 31, 2020 | 17.12M | 9.69M | 130.26% |
| Dec 31, 2019 | 7.44M | 3.60M | 94.07% |
| Dec 31, 2018 | 3.83M | 900.50K | 30.72% |
| Dec 31, 2017 | 2.93M | 449.41K | 18.11% |
| Dec 31, 2016 | 2.48M | -430.66K | -14.79% |
| Dec 31, 2015 | 2.91M | 1.42M | 94.66% |
| Dec 31, 2014 | 1.50M | 540.35K | 56.53% |
| Dec 31, 2013 | 955.88K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 99.34B |
| Eli Lilly and Company | 86.46B |
| Merck & Co. | 67.38B |
| AbbVie | 66.01B |
| Pomdoctor | 60.42M |
| XWELL | 28.28M |
| Sonoma Pharmaceuticals | 21.92M |
| Can-Fite BioPharma | 405.00K |
SCNX News
- 17 days ago - Scienture price target lowered to split-adjusted $6 at Maxim - TheFly
- 18 days ago - SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027 - GlobeNewsWire
- 27 days ago - Scienture reports preliminary Q3 revenue $1.22M, consensus $1.58M - TheFly
- 27 days ago - SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth - GlobeNewsWire
- 5 weeks ago - Scienture Holdings Inc trading halted, news pending - TheFly
- 5 weeks ago - Scienture’s Arbli added to formularies at 3 U.S. pediatric academic med centers - TheFly
- 5 weeks ago - SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals - GlobeNewsWire
- 5 weeks ago - Scienture announces reverse stock split - TheFly